Additionally, given that approximately 10% of elderly individuals have circulating NMDA receptor antibodies (IgA/IgM isotypes) (Ehrenreich, 2017; Sperber et al., 2019), our design may also reflect a situation of pre-existing antibody presence at stroke onset, which remains under debate regarding its impact on ischemic vulnerability or protection. Here, CD79A is linked to Stroke.